iiinova — where your digital self keeps evolving

Reposted by Antonella Cammarota

Lorenza Rimassa @lorenzarimassa.bsky.social · 24/01/2026

@acammarota.bsky.social presenting her work on clinical predictors and molecular architecture of #TLS in #CCA 🔬at @easlnews.bsky.social #LiverCancerSummit in Edinburgh. Great job! 👏🏻👏🏻👏🏻 #AnaLleo #HumanitasUniversity #Humanitas

021

Reposted by Antonella Cammarota

European Organisation for Research and Treatment of Cancer @eortc.org · 20/05/2025

On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward. 👩🏻‍⚕️ In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community. Learn more: www.eortc.org/blog/2025/05... ▶️ youtu.be/cjPQDCxrZbI

youtu.be

Meet the EORTC Early Career Investigators

YouTube video by EORTC

033

Reposted by Antonella Cammarota

Lorenza Rimassa @lorenzarimassa.bsky.social · 09/05/2025

Please have a look at our comment on #ICI and #TKI for unresectable #HCC published in @thelancetoncol.bsky.social @acammarota.bsky.social

021

Reposted by Antonella Cammarota

Eileen Parkes @eileenparkes.bsky.social · 03/02/2025

"Science is a career for anyone curious enough to ask why, and stubborn enough to keep on asking." Yes, love this

0176

Reposted by Antonella Cammarota

Nuria Lopez-Bigas @nlbigas.bsky.social · 27/11/2024

Only a subset of patients respond to immunotherapy Why? Which ones? We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response. www.nature.com/articles/s41...

413246

Reposted by Antonella Cammarota

Lizzy Smyth @lizzysmyth.bsky.social · 29/11/2024

Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏 Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show: ✅Strong link between PD-L1 and pathological response. ✖️ Less so OS .. www.esmogastro.org/article/S294... Looking forward to MATTERHORN next year!

esmogastro.org

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials

Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor (ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma (GEA) with unclear ou...

1102